Biotec is a research organisation in Lasne. Public Limited, started on 17 July 1975, 1 establishment.

What is the address of Biotec?

The registered office of Biotec is located at Chaussée de Louvain 656, 1380 Lasne.

Is Biotec still active?

Yes. According to the CBE (29 October 2026) Biotec is active, legal situation “Normale toestand”, started on 17 July 1975.

Is Biotec registered on Peppol?

Yes, Biotec is registered on the Peppol network with ID 0208:0414938680.

What is the enterprise number of Biotec?

The enterprise number of Biotec is BE0414938680.

When was Biotec founded?

Biotec was founded on 17 July 1975.

Who are the directors of Biotec?

According to the 2024 annual accounts, the directors of Biotec are: Nathalie DELWART, Jean-Marie DELWART, Olivia DELWART, Charles-Emmanuel DELWART.

Is Biotec a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 July 1975; 4 annual accounts filed, latest fiscal year 2024; 4 directors known from the annual account.

How much profit did Biotec make in 2024?

Biotec posted a profit after taxes of € 1,452,538 in financial year 2024.

What is the revenue of Biotec?

As a small company, Biotec is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 543.

How many employees does Biotec have?

According to the 2024 annual accounts, Biotec has 0.7 full-time equivalents (FTE).

Biotec (Public Limited) - Lasne - BE0414938680

Dossier Biotec, printed on 29 October 2026 from databakkes.be/en/0414938680/biotec. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 28 % of short-term debt in 2024; threshold 65 %.

Financials

Financial year 2024

Biotec from Lasne, company number BE0414938680, closed financial year 2024 with a result of € 1.5 million after tax. For that financial year Biotec recorded a gross margin of € 543 and equity of € 4.1 million. Compared with financial year 2023, the result moved from € 12,210 to € 1.5 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2025.

What it is worth Growing

€ 4.1 million

▲ 54% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 1.5 million

▲ € 1.4 million vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 152,908

▲ 13% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € -5.4 million.

People and assets in 2024

Full-time equivalents

0.7

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 59,032

▲ 2% vs 2023

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 2,103

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt

€ 624,363

▼ 48% vs 2023

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 1,551

▲ 11% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 15,925

▲ 17% vs 2023

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ -12,030 Gross margin 2021: € -12,030 First fiscal year in the series	€ -40,996 Gross margin 2022: € -40,996 ▼ € 28,966 vs 2021 (€ -12,030) Unfavourable step	€ -8,275 Gross margin 2023: € -8,275 ▲ € 32,721 vs 2022 (€ -40,996) Favourable step	€ 543 Gross margin 2024: € 543 ▲ € 8,818 vs 2023 (€ -8,275) Favourable step	▲ € 8,818
Profit after taxes	€ 67,925 Profit after taxes 2021: € 67,925 First fiscal year in the series	€ -281,799 Profit after taxes 2022: € -281,799 ▼ € 349,723 vs 2021 (€ 67,925) Unfavourable step	€ 12,210 Profit after taxes 2023: € 12,210 ▲ € 294,009 vs 2022 (€ -281,799) Favourable step	€ 1,452,538 Profit after taxes 2024: € 1,452,538 ▲ € 1.4 million vs 2023 (€ 12,210) Favourable step	▲ € 1.4 million
Equity	€ 2,936,506 Equity 2021: € 2,936,506 First fiscal year in the series	€ 2,654,707 Equity 2022: € 2,654,707 ▼ 10% vs 2021 (€ 2,936,506) Unfavourable step	€ 2,666,917 Equity 2023: € 2,666,917 Unchanged (€ 2,654,707) Favourable step	€ 4,119,455 Equity 2024: € 4,119,455 ▲ 54% vs 2023 (€ 2,666,917) Favourable step	▲ 54%
Total debts	€ 4,544,952 Total debts 2021: € 4,544,952 First fiscal year in the series	€ 2,794,290 Total debts 2022: € 2,794,290 ▼ 39% vs 2021 (€ 4,544,952) Favourable step	€ 3,470,556 Total debts 2023: € 3,470,556 ▲ 24% vs 2022 (€ 2,794,290) Unfavourable step	€ 1,487,495 Total debts 2024: € 1,487,495 ▼ 57% vs 2023 (€ 3,470,556) Favourable step	▼ 57%
Cash	€ 53,644 Cash 2021: € 53,644 First fiscal year in the series	€ 392,360 Cash 2022: € 392,360 ▲ € 338,715 vs 2021 (€ 53,644) Favourable step	€ 135,107 Cash 2023: € 135,107 ▼ 66% vs 2022 (€ 392,360) Unfavourable step	€ 152,908 Cash 2024: € 152,908 ▲ 13% vs 2023 (€ 135,107) Favourable step	▲ 13%
Land & buildings	-	€ 148,357 Land & buildings 2022: € 148,357 First fiscal year in the series	€ 148,357 Land & buildings 2023: € 148,357 Unchanged (€ 148,357) Unchanged	€ 148,357 Land & buildings 2024: € 148,357 Unchanged (€ 148,357) Unchanged
Retained profit	€ -6,604,231 Retained profit 2021: € -6,604,231 First fiscal year in the series	€ -6,886,030 Retained profit 2022: € -6,886,030 ▼ € 281,799 vs 2021 (€ -6,604,231) Unfavourable step	€ -6,873,820 Retained profit 2023: € -6,873,820 Unchanged (€ -6,886,030) Favourable step	€ -5,421,282 Retained profit 2024: € -5,421,282 ▲ € 1.5 million vs 2023 (€ -6,873,820) Favourable step	▲ € 1.5 million
Bank debt	€ 2,073,765 Bank debt 2021: € 2,073,765 First fiscal year in the series	€ 475,956 Bank debt 2022: € 475,956 ▼ 77% vs 2021 (€ 2,073,765) Favourable step	€ 1,211,416 Bank debt 2023: € 1,211,416 ▲ 155% vs 2022 (€ 475,956) Unfavourable step	€ 624,363 Bank debt 2024: € 624,363 ▼ 48% vs 2023 (€ 1,211,416) Favourable step	▼ 48%
Balance sheet total	€ 7,481,458 Balance sheet total 2021: € 7,481,458 First fiscal year in the series	€ 5,448,997 Balance sheet total 2022: € 5,448,997 ▼ 27% vs 2021 (€ 7,481,458) Unchanged	€ 6,137,473 Balance sheet total 2023: € 6,137,473 ▲ 13% vs 2022 (€ 5,448,997) Unchanged	€ 5,606,949 Balance sheet total 2024: € 5,606,949 ▼ 9% vs 2023 (€ 6,137,473) Unchanged	▼ 9%
Employees (FTE)	0.7 Employees (FTE) 2021: 0.7 First fiscal year in the series	0.7 Employees (FTE) 2022: 0.7 Unchanged (0.7) Unchanged	0.7 Employees (FTE) 2023: 0.7 Unchanged (0.7) Unchanged	0.7 Employees (FTE) 2024: 0.7 Unchanged (0.7) Unchanged

Key figures of Biotec, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to Biotec?

What happened at Biotec in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2031 Nathalie DELWART stepped down as director. NBB
2031 Olivia DELWART stepped down as director. NBB
2031 Charles-Emmanuel DELWART stepped down as director. NBB
Jul 31, 2025 New annual accounts for financial year 2024: profit of € 1.5 million (▲ € 1.4 million vs 2023). Source: NBB ↗
2025 Nathalie DELWART became a director. NBB
2025 Olivia DELWART became a director. NBB
2025 Charles-Emmanuel DELWART became a director. NBB
2025 Jean-Marie DELWART stepped down as director. NBB

In short

From € 67,925 profit in 2021 to € 1.5 million profit in 2024.

Paid € 37,855 in corporate taxes since 2021.

Best year ever: 2024, with € 1.5 million profit.

Original PDFs at the National Bank ↗

Management

Belgocodex SA 78.5%

Belgobio 14.8%

The stake of Belgobio comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Biotec

PHARMACIE DU VERT CHASSEUR 30.9%

CHEMCOM 20.3%

DOMAINE D'ARGENTEUIL 16.8%

The shares are held by Belgocodex SA (78.5%) and Belgobio (14.8%). It owns 30.9% of PHARMACIE DU VERT CHASSEUR, 20.3% of CHEMCOM and 16.8% of DOMAINE D'ARGENTEUIL itself.

Directors

According to the 2024 annual accounts

Nathalie DELWART

Managing director

Also active at: Belgocodex, ALANINE, DOMAINE D'ARGENTEUIL

since 2025 · until 2031

Jean-Marie DELWART

Managing director

· until 2025

Olivia DELWART

Managing director

Also active at: Belgocodex, ALANINE, DOMAINE D'ARGENTEUIL

since 2025 · until 2031

Charles-Emmanuel DELWART

Managing director

Also active at: Belgocodex, ALANINE, GREENBE, DOMAINE D'ARGENTEUIL

since 2025 · until 2031

Shareholders

Belgocodex SA

78.5%

Belgobio

14.8%

Participations

PHARMACIE DU VERT CHASSEUR

30.9%

CHEMCOM

20.3%

DOMAINE D'ARGENTEUIL

16.8%

Establishments

Establishment units

Physical locations of this company

Registered office

Chaussée de Louvain 656

1380 Lasne

2.038.182.410

Drève Richelle 161 box 10

1410 Waterloo

Active since 6 October 1992

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

Belgocodex same network

€ -103,202 gross margin · 2024

ALANINE same network

€ -6,981 gross margin · 2025

GREENBE same network

€ 850,440 gross margin · 2025

Belgobio same network

€ -10,134 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0414.938.680

VAT number

BE 0414.938.680

Registered office

Chaussée de Louvain 656, 1380 Lasne

Names & denominations

Biotec

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

17 July 1975

Peppol

Active · Active since 15 Oct 2025

Activities · NACE

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Speur- en ontwikkelingswerk op biotechnologisch gebied

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

Biotec

Warning lights

Financials

What happened to Biotec?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions